
March 12 (Reuters) - Lipocine Inc LPCN.O:
LIPOCINE ANNOUNCES FDA LABELING CHANGES FOR TESTOSTERONE PRODUCTS
LIPOCINE: FDA RECOMMENDED BOXED WARNING RELATED TO INCREASED RISK OF ADVERSE CARDIOVASCULAR OUTCOMES BE REMOVED FROM LABELS OF TESTOSTERONE PRODUCTS
LIPOCINE: FDA IS ALSO REQUIRING ALL LABELS TO INCLUDE PRODUCT-SPECIFIC INFORMATION ON INCREASED BLOOD PRESSURE FOR TESTOSTERONE PRODUCTS